ISV C-Terminal Modification for ADA Assay Interference
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting anti-drug antibodies (ADA) in immunoglobulin single variable domains (ISV) are hindered by aspecific protein interference, which complicates the assessment of immunogenic potential and treatment monitoring in clinical trials and therapeutic settings.
Innovation Solution
The development of assays and modifications that utilize an analytical antibody to predict and reduce protein interference by adding amino acid residues to the C-terminal end of ISV domains, such as a single alanine residue, to minimize hydrophobic patches and B-cell epitopes, thereby enhancing the accuracy of ADA assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If ISV domains are used in ADA assays, then the ability to detect anti-drug antibodies is improved, but asspecific protein interference increases
Solution Approach 1:
The patent applies local quality by making a specific modification at the C-terminal end of the ISV domain (adding amino acid residues) to reduce asspecific protein binding. This localized modification addresses the interference problem without altering the overall structure or antigen-binding function of the ISV domain, thereby maintaining detection accuracy while reducing harmful protein interference.
Solution Approach 2:
The patent changes the physical-chemical parameters of the ISV domain by adding amino acid residues (such as alanine) to the C-terminal end. This parameter change modifies the hydrophobicity and charge characteristics of the C-terminal region, reducing asspecific protein interactions while preserving the ISV's ability to detect anti-drug antibodies.
2Object-affected harmful factors
If amino acid residues are added to the C-terminal end of ISV domains, then protein interference is reduced, but the complexity of the ISV structure increases
Solution Approach 1:
The patent applies partial action by adding only a small number of amino acid residues (such as one or more alanine residues) to the C-terminal end of the ISV domain. This minimal modification is sufficient to reduce asspecific protein interference without substantially increasing the overall complexity of the ISV structure, maintaining simplicity while achieving the desired effect.
3Loss of information
If ISV domains are used to monitor treatment, then the ability to assess pharmacological properties is improved, but reliability of assay results decreases due to protein interference
Solution Approach 1:
The patent applies local quality by modifying only the C-terminal region of the ISV domain to reduce asspecific protein binding. This localized change eliminates the source of interference that compromises result reliability, while preserving the ISV's ability to accurately monitor treatment and assess pharmacological properties.
Solution Approach 2:
The patent changes the electrostatic and hydrophobic parameters of the ISV C-terminal end by adding charged or hydrophilic amino acid residues. This parameter modification reduces non-specific protein interactions that cause false signals, thereby improving the reliability of assay results while maintaining the ISV's monitoring capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods effectively predict and reduce protein interference in ADA assays, allowing for more reliable detection of anti-drug antibodies and improved monitoring of ISV-based treatments, ensuring accurate pharmacological properties and treatment efficacy.
Implementation Method 1
contacting said ISV or Nanobody (or ISV-based or Nanobody-based drug) with an antibody that has been obtained from a human subject and that has been selected, generated and/or isolated based on its ability to recognize and/or bind to the C-terminal end of an ISV or Nanobody
Implementation Method 2
adding amino acid residues to the C-terminal end of ISV domains, such as a single alanine residue, to minimize hydrophobic patches and B-cell epitopes
Data Source
AI summary
This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.